Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date. three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally. https://www.learningepistemology.com/product-category/wipes/